Home - Products - Others - Other Targets - Upifitamab

Upifitamab

CAS No. 2254118-43-7

Upifitamab( —— )

Catalog No. M37099 CAS No. 2254118-43-7

Upifitamab is a naked antibody to upifitamab rilsodotin, which can be used to synthesize the antibody-coupled active molecule UPRI, which can be used to study cancer.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	527	Get Quote
5MG	796	Get Quote
10MG	1036	Get Quote
25MG	1279	Get Quote
50MG	1730	Get Quote
100MG	2277	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Upifitamab
Note

Research use only, not for human use.
Brief Description

Upifitamab is a naked antibody to upifitamab rilsodotin, which can be used to synthesize the antibody-coupled active molecule UPRI, which can be used to study cancer.
Description

Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

ADC Antibody
Research Area

——
Indication

——

Chemical Information

CAS Number

2254118-43-7
Formula Weight

Approximately 144.74 kDa.
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Richardson D, et al. Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076). Gynecologic Oncology, 2022, 166: S48.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Miraculan

Triacontan-1-ol is an active biochemical.
CCF0058981

CCF0058981 is a SARS-CoV-2 inhibitor with low nanomolar biochemical inhibition and efficacy in cellular models comparable to that of Remdesivir.
BT173

BT173 is a novel inhibitor of homeodomain interacting protein kinase 2 (HIPK2 ), attenuating renal fibrosis through suppression of the TGF-?1/Smad3 pathway.

Sign In Join Free